Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMAUMUS-ROBERT, Sandy
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorJARNE MUNOZ, Ana
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
dc.contributor.authorDUROUX, Thomas
dc.contributor.authorDURANTEAU, Lise
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEZIN, Julien
dc.date.accessioned2023-12-18T12:30:14Z
dc.date.available2023-12-18T12:30:14Z
dc.date.issued2023-09-25
dc.identifier.issn1664-2392en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/186696
dc.description.abstractEnINTRODUCTION: Statins could reduce the synthesis of steroid hormones, thereby could cause adrenal insufficiency. We investigated this risk in a large nationwide database. METHODS: We conducted a nested case-control study using a cohort of individuals affiliated to the French health insurance system in 2010, ≥18y and without adrenal insufficiency history. Each case had a first event of adrenal insufficiency between 2015 and 2017 and was matched to up to ten controls on age, sex, and prior treatment with corticosteroids. Statin exposure was measured over the five years preceding the index date, considering a six-month censoring lag-time. Association was estimated using a conditional logistic regression adjusted for confounders included in a disease risk score. Analyses were stratified on age, sex and corticosteroid history of use. RESULTS: 4 492 cases of adrenal insufficiency were compared with 44 798 controls (median age 66y, 58% women), of which 39% vs. 33% were exposed to statins, respectively. No association between statin use and adrenal insufficiency was found when adjusting the model for confounders (adjusted odds ratio 0.98; 95% confidence interval 0.90-1.05). These results were consistent regardless of the exposure definition and stratifications considered. CONCLUSION: Statin-related adrenal insufficiency risk, if any, seems to be very limited and does not compromise the benefit of statin treatment.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enAdrenal insufficiency
dc.subject.enDatabase
dc.subject.enPharmacoepidemiology
dc.subject.enRisk
dc.subject.enStatins
dc.title.enStatin treatment is not associated with an increased risk of adrenal insufficiency in real-world setting
dc.title.alternativeFront Endocrinol (Lausanne)en_US
dc.typeArticle de revueen_US
dc.identifier.doi10.3389/fendo.2023.1254221en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed37818086en_US
bordeaux.journalFrontiers in Endocrinologyen_US
bordeaux.page1254221en_US
bordeaux.volume14en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDAgence Nationale de Sécurité du Médicament et des Produits de Santéen_US
hal.identifierhal-04350441
hal.version1
hal.date.transferred2023-12-18T12:30:16Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers%20in%20Endocrinology&rft.date=2023-09-25&rft.volume=14&rft.spage=1254221&rft.epage=1254221&rft.eissn=1664-2392&rft.issn=1664-2392&rft.au=MAUMUS-ROBERT,%20Sandy&JARNE%20MUNOZ,%20Ana&PARIENTE,%20Antoine&DUROUX,%20Thomas&DURANTEAU,%20Lise&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée